These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3708036)

  • 41. Impaired lymphocyte stimulation by mitogens in severely depressed patients. A complex interface with HPA-axis hyperfunction, noradrenergic activity and the ageing process.
    Maes M; Bosmans E; Suy E; Minner B; Raus J
    Br J Psychiatry; 1989 Dec; 155():793-8. PubMed ID: 2620206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The dexamethasone suppression test and pituitary-adrenocortical function.
    Brown WA; Keitner G; Qualls CB; Haier R
    Arch Gen Psychiatry; 1985 Feb; 42(2):121-3. PubMed ID: 3977539
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dexamethasone suppression test in psychotic versus non-psychotic endogenous depression.
    Rihmer Z; Arató M; Szádoczky E; Révai K; Demeter E; György S; Udvarhelyi P
    Br J Psychiatry; 1984 Nov; 145():508-11. PubMed ID: 6498417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progressive dysregulation of autonomic and HPA axis functions in HIV-1 clade C infection in South India.
    Chittiprol S; Kumar AM; Satishchandra P; Taranath Shetty K; Bhimasena Rao RS; Subbakrishna DK; Philip M; Satish KS; Ravi Kumar H; Kumar M
    Psychoneuroendocrinology; 2008 Jan; 33(1):30-40. PubMed ID: 17993249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adrenocortical function and plasma norepinephrine in normal human subjects.
    Sotsky SM; Lake CR; Goodwin FK
    Biol Psychiatry; 1981 Jul; 16(7):643-51. PubMed ID: 7272380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?
    Maes M; Bosmans E; Meltzer HY; Scharpé S; Suy E
    Am J Psychiatry; 1993 Aug; 150(8):1189-93. PubMed ID: 8328562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dexamethasone suppression test findings in subjects with personality disorders: associations with posttraumatic stress disorder and major depression.
    Grossman R; Yehuda R; New A; Schmeidler J; Silverman J; Mitropoulou V; Sta Maria N; Golier J; Siever L
    Am J Psychiatry; 2003 Jul; 160(7):1291-8. PubMed ID: 12832244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression.
    Bschor T; Baethge C; Adli M; Eichmann U; Ising M; Uhr M; Müller-Oerlinghausen B; Bauer M
    Depress Anxiety; 2003; 17(1):43-8. PubMed ID: 12577277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of the DST results in depressives by means of urinary-free cortisol excretion, dexamethasone levels, and age.
    Maes M; Jacobs MP; Suy E; Minner B; Raus J
    Biol Psychiatry; 1990 Aug; 28(4):349-57. PubMed ID: 2397250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The plasma dexamethasone window: evidence supporting its usefulness to validate dexamethasone suppression test results.
    O'Sullivan BT; Hunt GE; Johnson GF; Caterson ID
    Biol Psychiatry; 1989 Mar; 25(6):739-54. PubMed ID: 2923936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels.
    Holsboer-Trachsler E; Buol C; Wiedemann K; Holsboer F
    Acta Psychiatr Scand; 1987 Jun; 75(6):608-13. PubMed ID: 3618283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dexamethasone suppression test in children with major depressive disorder.
    Birmaher B; Ryan ND; Dahl R; Rabinovich H; Ambrosini P; Williamson DE; Novacenko H; Nelson B; Lo ES; Puig-Antich J
    J Am Acad Child Adolesc Psychiatry; 1992 Mar; 31(2):291-7. PubMed ID: 1564032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypothalamic-pituitary-adrenal axis activity and tricyclic response in major depression.
    Nelson WH; Orr WW; Stevenson JM; Shane SR
    Arch Gen Psychiatry; 1982 Sep; 39(9):1033-6. PubMed ID: 7115012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients.
    Jokinen J; Nordström P
    J Affect Disord; 2009 Jul; 116(1-2):88-92. PubMed ID: 19054568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive impairment and cortisol levels in first-episode schizophrenia patients.
    Havelka D; Prikrylova-Kucerova H; Prikryl R; Ceskova E
    Stress; 2016 Jul; 19(4):383-9. PubMed ID: 27320489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The lower limits of dexamethasone window in Chinese depressives.
    Shiah IS; Ko HC; Lu RB
    Biol Psychiatry; 1998 Oct; 44(7):648-55. PubMed ID: 9787892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dexamethasone nonsuppression in chronic schizophrenia.
    Whiteford HA; Riney SJ; Savala RA; Csernansky JG
    Acta Psychiatr Scand; 1988 Jan; 77(1):58-62. PubMed ID: 3273153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The dexamethasone suppression test in schizophrenia.
    Sawyer J; Jeffries JJ
    J Clin Psychiatry; 1984 Sep; 45(9):399-402. PubMed ID: 6469927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dexamethasone suppression test in depression and other psychiatric illness.
    Coppen A; Abou-Saleh M; Milln P; Metcalfe M; Harwood J; Bailey J
    Br J Psychiatry; 1983 May; 142():498-504. PubMed ID: 6409195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The specificity of the dexamethasone suppression test in endogenous depressive patients.
    Lu RB; Ho SL; Huang HC; Lin YT
    Neuropsychopharmacology; 1988 May; 1(2):157-62. PubMed ID: 3251496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.